长期使用阿奇霉素治疗肺移植受者的闭塞性细支气管炎综合征。
Long-term azithromycin use for treatment of bronchiolitis obliterans syndrome in lung transplant recipients.
作者信息
Shitrit David, Bendayan Daniele, Gidon Sahar, Saute Milton, Bakal Ilana, Kramer Mordechai R
机构信息
Pulmonary Institute, Rabin Medical Center, Beilinson Campus, Petach Tikva, Israel.
出版信息
J Heart Lung Transplant. 2005 Sep;24(9):1440-3. doi: 10.1016/j.healun.2004.08.006.
Short-term improvement in lung function was observed in 5 of 6 lung transplant recipients with bronchiolitis obliterans syndrome (BOS) who were treated with oral azithromycin. We assessed the long-term effect (mean duration 10 months) of treatment with oral azithromycin in 11 lung transplant recipients with BOS. Mean forced expiratory volume in 1 second (FEV1) was 40 +/- 9% at initiation of azithromycin treatment, 39 +/- 10% after 1 month, 39 +/- 12% after 4 months, 38 +/- 10% after 7 months and 38 +/- 10% after 10 months, respectively (statistically non-significant for all data). We conclude that long-term administration with oral azithromycin does not reverse BOS in lung transplant recipients, but may slow progression of the disease.
在6例患有闭塞性细支气管炎综合征（BOS）的肺移植受者中，有5例接受口服阿奇霉素治疗后肺功能出现短期改善。我们评估了11例患有BOS的肺移植受者接受口服阿奇霉素治疗的长期效果（平均持续时间10个月）。在开始阿奇霉素治疗时，第1秒用力呼气量（FEV1）平均为40±9%，1个月后为39±10%，4个月后为39±12%，7个月后为38±10%，10个月后为38±10%（所有数据在统计学上均无显著差异）。我们得出结论，长期口服阿奇霉素并不能逆转肺移植受者的BOS，但可能会减缓疾病进展。
Zotero 插件